Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528770 | 0.91 | KCNH2 (0.40) | KCNH2HRH3ADORA2BMAPK14ADORA2A | |
| SCHEMBL4091561 | 0.81 | MAPK1 (0.39) | KCNH2MAPK14PRKCZKMT2APRKD1 | |
| SCHEMBL4103384 | 0.72 | ALDH1A1 (0.57) | ADORA2BMAPK14ADORA2AKMT2AMAP4K4 | |
| SCHEMBL4092218 | 0.72 | ADORA2B (0.52) | ADORA2BMAPK14ADORA2AMAP4K4MINK1 | |
| SCHEMBL17297196 | 0.68 | BRAF (0.43) | — | |
| SCHEMBL6215634 | 0.67 | MAPK14 (0.51) | KCNH2MAPK14 | |
| SCHEMBL30576100 | 0.66 | ITGB2 (0.49) | MAPK14PRKD1 | |
| SCHEMBL12491446 | 0.65 | AR (0.50) | KMT2A | |
| SCHEMBL12041777 | 0.63 | HRH3 (0.71) | KCNH2HRH3 | |
| SCHEMBL5205345 | 0.63 | TGFBR1 (0.53) | KCNH2ADORA2BMAPK14ADORA2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | KCNH2 2790/4885HRH3 1828/4885ADORA2B 4778/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | KCNH2 2790/4885HRH3 1828/4885ADORA2B 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.